Fig 1.
Diagram of case selection based on a) urine bioassay measurements, b) post-mortem plutonium activity concentrations in the liver and skeleton, c) both criteria.
Fig 2.
Urine measurements as a function of time after employment start date.
Each chronic exposure period is indicated by the gray area (start day 0 not shown). Real measurements are displayed as circles with error bars above and below, <MDA/2 are displayed as squares with error bar below.
Table 1.
Summary of urine bioassay measurements.
Table 2.
Summary of the tissue radiochemical analysis results.
Table 3.
Plutonium activities in the liver, skeleton, and liver+skeleton at the time of death predicted using urine bioassay.
Fig 3.
Bias in liver (left) and skeleton (right) activities predicted from urine bioassays.
Fig 4.
Bias in liver+skeleton activities predicted from urine bioassays.
Table 4.
Committed effective doses calculated using five different sets of data.
Fig 5.
Position of committed effective dose EU+LS between ELS and EU (Bq d–1).
Vertical dotted line at 50% indicates the average of ELS and EU.
Table 5.
Absorbed lifetime and 50-y projected doses to selected organs.
Fig 6.
Skeleton-to-liver 239Pu activity ratio.